Demonstration of a new diagnostic device for the Overactive Bladder syndrome

Informazioni relative al progetto

OABCAP

ID dell’accordo di sovvenzione: 663530

DOI

10.3030/663530

Progetto chiuso

Data della firma CE 6 Febbraio 2015

Data di avvio 1 Marzo 2015

Data di completamento 31 Agosto 2015

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

ALBYN MEDICAL, S.L.
Spain

Periodic Reporting for period 1 - OABCAP (Demonstration of a new diagnostic device for the Overactive Bladder syndrome)

Periodo di rendicontazione: 2015-03-01 al 2015-08-31

Sintesi del contesto e degli obiettivi generali del progetto

This report describes the results of the feasibility study for the commercialisation of the OABCAP diagnostic device for the Overactive Bladder syndrome.

The feasibility study has been carried out in a working group formed by the consultancy and the company:

• By the consultancy BANTEC GROUP, the members of the team have been the following:
- Senior consultant
- Senior consultant

• By the technology and product owner ALBYN MEDICAL, the members of the team have been the following:
- General Manager
- Administration manager

Five face-to-face meetings have been carried out with specific themes:

1. Feasibility study launch – March 2014
2. Market – March 2014
3. Value proposition, business model and commercialisation – May 2015
4. Costs, revenues and funding scheme – June 2015
5. Results validation – August 2015

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

Performed actions within the feasibility study are summarized in the following points:

• Market: The related market to the new product has been analysed and its volume forecast for 2020 has been determined.

• Opportunity: The opportunity of OABCAP in the current urologic equipment and disposables market has been analysed.

• Competition: The characteristics of the competitors’ products have been analysed taking as reference the ALBYN MEDICAL new product.

• Regulatory risk: The regulatory risks have been analysed for each significant market.

• Added value: The OABCAP added value has been established taking into account the current market solutions and their limitations.

• Intellectual property: The freedom to operate analysis has been reviewed to establish the up-to-date status of the protection.

• Business model: Current business model in the market have been analysed and the optimum business model for the commercialisation of the new product has been established.

• Commercialisation: A commercialisation strategy has been established.

• Risks: Main technical and regulatory risks have been determined and specific contingency plans have been defined.

• Resources: Manufacture and sale resources for the commercialisation of the new product have been identified.

• Return on the investment: Sales projections hypothesis, cost structure and the revenue model have been established. The return on the investment has been analysed and the business feasibility has been confirmed.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

The new diagnostic device:

• Will determine with high reliability if the patient suffers Overactive Bladder syndrome.

• Will highly decrease the impact of the test in the patient (discomfort).

Thanks to the new diagnostic device a reliable diagnostic evaluation is obtained and thus high treatment costs of the over-diagnosis are avoided improving the sustainability of the European Health and Care systems.
Based on the feasibility study carried out, the business feasibility can be ensured.

oabcap.png